Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-I–null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer

High levels of high-density lipoprotein (HDL) have protective effects against atherosclerosis and cardiovascular diseases. The postulated mechanism of action for these benefits is an enhanced reverse cholesterol transport. Apolipoprotein A-I (ApoA-I) is the major protein of HDL. The clinical benefits of raising ApoA-I/HDL have been clearly established by clinical and epidemiological studies. Despite these observations, there are not very effective pharmacological means for raising HDL. ApoA-I gene delivery by viral vectors seems a promising strategy to raise ApoA-I/HDL levels. Sustained gene expression in animals and humans has been attained using adeno-associated viral (AAV) vectors. The aim of the present study was to determine the efficiency, safety, and biological activity of human ApoA-I intramuscularly delivered using an AAV vector in mice. AAV serotype 8 vectors encoding for human ApoA-I transgene were administered intraportally and intramuscularly in ApoA-I-deficient animals. ApoA-I levels were measured every 2 weeks post administration. The effectiveness of the generated HDL was tested in vitro in cholesterol-loaded macrophages. The administration of the vectors resulted in a significant and sustained increase in ApoA-I and HDL plasma levels for up to 16 weeks at similar extent by both routes of administration. Activity of the generated HDL in removal of cholesterol from cholesterol-loaded macrophages was similar in both groups. Our data suggest that intramuscular AAV8-mediated gene transfer of human ApoA-I results in a significant and maintained increase in ApoA-I and functional HDL.

[1]  S. Vaessen,et al.  AAV gene therapy as a means to increase apolipoprotein A-I and high-density lipoprotein- cholesterol levels: Correction of murine apoA-I deficiency , 2009 .

[2]  Z. Xiang,et al.  A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  V. Fuster,et al.  Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano , 2008, Journal of cellular and molecular medicine.

[4]  J. Kira,et al.  Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Borja Ibanez,et al.  HDL-cholesterol: is it really good? Differences between apoA-I and HDL. , 2008, Biochemical pharmacology.

[6]  Michael Hallek,et al.  Recent developments in adeno‐associated virus vector technology , 2008, The journal of gene medicine.

[7]  P. Venkatesh,et al.  Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. , 2008, The American journal of the medical sciences.

[8]  D. Yellon,et al.  Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels , 2008, Postgraduate Medical Journal.

[9]  T. Flotte,et al.  Clinical gene therapy using recombinant adeno-associated virus vectors , 2008, Gene Therapy.

[10]  M. Shakibaei,et al.  Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy , 2008, Circulation.

[11]  Gemma Vilahur,et al.  Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.

[12]  E. Fisher,et al.  Atheroprotective effects of HDL: beyond reverse cholesterol transport. , 2008, Current drug targets.

[13]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[14]  D. Rader,et al.  Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent , 2007, Cardiovascular diabetology.

[15]  Colin Berry,et al.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.

[16]  Zui Tan,et al.  Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs , 2007, Acta Pharmacologica Sinica.

[17]  J. Gray,et al.  Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. , 2007, Blood.

[18]  J. Wilson,et al.  Efficacy and safety of adeno‐associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy , 2006, Journal of thrombosis and haemostasis : JTH.

[19]  Z. Cao,et al.  A comparative study of hFIX expression mediated by rAAV8 and rAAV1 administrated intramuscularly. , 2007, Cytotherapy.

[20]  D. Rader,et al.  Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. , 2006, Atherosclerosis.

[21]  H. Kazazian,et al.  Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. , 2006, Human gene therapy.

[22]  D. Rader,et al.  New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.

[23]  Lili Wang,et al.  Gene transfer into skeletal muscle using novel AAV serotypes , 2005, The journal of gene medicine.

[24]  Theresa A. Storm,et al.  Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice , 2005, Journal of Virology.

[25]  M. Hayden,et al.  Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. , 2004, Human gene therapy.

[26]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[27]  A. Beaudet,et al.  Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia , 2003, Circulation.

[28]  D. Collen,et al.  Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector , 2002, Gene Therapy.

[29]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Blancho,et al.  Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  R. Samulski,et al.  Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  R. Herzog,et al.  Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  D. Collen,et al.  Sustained expression of human apo A-I following adenoviral gene transfer in mice , 2001, Gene Therapy.

[34]  R. Samulski,et al.  Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia , 1998, Gene Therapy.

[35]  P. Clarkson,et al.  Variability in serum creatine kinase response after eccentric exercise of the elbow flexors. , 1996, International journal of sports medicine.

[36]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[37]  T D Noakes,et al.  Effect of Exercise on Serum Enzyme Activities in Humans , 1987, Sports medicine.

[38]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.